Ipamorelin dosage as the research reports it

Read this first

This page describes the Ipamorelin dosage figures that appear in published studies. It does not tell anyone how much to use. Ipamorelin is not an approved medicine, there is no established human dose, and the doses below were given to specific species — rats, ferrets, fish, or a small number of human volunteers — under controlled study conditions. They are written here in plain, third-person terms so a reader can understand what was actually administered.

A few anchors help. In the one human pharmacokinetic study, the terminal half-life — the time for the blood level to fall by half in the elimination phase — was about 2 hours, and growth hormone rose as a single pulse peaking near 40 minutes ^[2]. Community 'stack' protocols that pair ipamorelin with CJC-1295 have no peer-reviewed human dosing basis whatsoever; they are anecdote, and this page treats them as such.

Doses studied, by model

Across the literature the studied doses span a wide range because the species and goals differ. In the human PK/PD study, healthy male volunteers received single 15-minute intravenous infusions of 4.21-140.45 nmol/kg ^[2]. In the only human efficacy trial, adults undergoing bowel resection received 0.03 mg/kg intravenously twice daily for up to 7 days ^[3]. In a rat longitudinal-bone-growth study, subcutaneous doses of 18, 90, and 450 microg/day (divided three times daily for 15 days) raised the bone growth rate dose-dependently from 42 microm/day in vehicle to 44, 50, and 52 microm/day ^[4]. The 2024 ferret cachexia study used 1-3 mg/kg intraperitoneally ^[5]. A tilapia reproductive study used 5 or 30 microg per animal over 21 days ^[15]. Each of these is a study dose in a defined model — not a template for human use.

Routes studied

Ipamorelin has been administered by several routes in research. Intravenous dosing dominates the human PK and clinical-trial work and the rodent efficacy studies ^[2][3]. Subcutaneous dosing is the route in rodent bone and body-composition studies, and is the dominant route in off-label community use ^[4]. Intranasal dosing has been characterized in rodents at roughly 20% bioavailability, and intraperitoneal dosing appears in rodent and ferret efficacy studies ^[5]. Ipamorelin itself is not orally bioavailable; only engineered ipamorelin-derived analogs show meaningful oral absorption (around 10% in dog). The route matters because it shapes both the size and the timing of the growth-hormone pulse.

Half-life and kinetics

The human kinetic profile is one of the few well-defined parts of the record. Population PK/PD modeling in healthy male volunteers (n=8 per dose level) showed dose-proportional kinetics with a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg ^[2]. The growth-hormone response was a single discrete pulse peaking at roughly 0.67 hours — about 40 minutes — after dosing ^[2]. In rats, plasma clearance is roughly five-fold lower than that of GHRP-6. These figures describe how the molecule moves through the body; they are pharmacology, not a dosing schedule.

How much cjc-1295 ipamorelin should i take

There is no research-grounded answer to how much cjc-1295 ipamorelin should i take, and this site will not invent one. No controlled human trial has established a dose for the combination, and the only human ipamorelin trial used a fixed intravenous research dose (0.03 mg/kg twice daily) for a hospital indication that failed ^[3]. The subcutaneous 'stack' regimens circulated in forums rest on no peer-reviewed human dosing basis; they are anecdotal community practice. Describing them as a recommendation would misrepresent the evidence — the honest statement is that a validated human dose does not exist.

How to reconstitute cjc-1295 ipamorelin 5mg

On how to reconstitute cjc-1295 ipamorelin 5mg: ipamorelin is supplied as a lyophilized (freeze-dried) powder, as either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction and not a direction for human use. The specific 5 mg figure refers to a vial mass commonly sold to researchers; this page does not provide injection or self-administration guidance.